Colgate-Palmolive Company (CL)
Colgate-Palmolive: Still A Buy As The 2030 Growth Strategy Begins
Colgate-Palmolive remains a Buy as it enters its next 5-year plan, leveraging strong brands and resilient financials. Q4 earnings beat expectations, with record cash flow from operations and robust performance in emerging markets driving a 5.9% revenue increase. Guidance reflects uncertainty, projecting 2–6% net sales growth and 1–4% organic sales growth, while CL advances its $5B buyback and maintains a solid payout.
Why Colgate-Palmolive (CL) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Colgate-Palmolive (CL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Colgate-Palmolive Company (CL) Q4 2025 Earnings Call Transcript
Colgate-Palmolive Company (CL) Q4 2025 Earnings Call Transcript
Colgate Q4 Earnings Top Estimates, Strong Pricing Drives Results
CL's Q4 earnings beat estimates as strong pricing and brand leadership lifted sales, with solid gains in Latin America and resilient global demand.
Colgate-Palmolive (CL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Colgate-Palmolive (CL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Colgate-Palmolive (CL) Q4 Earnings and Revenues Surpass Estimates
Colgate-Palmolive (CL) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.91 per share a year ago.
Colgate-Palmolive Swings to a Loss on Charges
Colgate-Palmolive swung to a loss in the fourth quarter, hurt by a large charge tied to its struggling skin-health business, but sales climbed despite what the company says is a difficult environment.
Colgate's Q4 Earnings Around the Corner: What Investors Should Know?
CL heads into Q4 earnings with pricing, innovation and productivity efforts supporting growth, while inflation, tariffs and volume softness weigh on margins.
Colgate-Palmolive (CL) Reports Next Week: What You Should Expect
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 “Forever Stocks” to Hold When the Market Won't Sit Still
With so much volatility in the market, it's a good time for investors to consider stocks that they can hold for the long haul. These compounders don't have to make up a large part of your portfolio, but they're good stocks to have for investors who like to step away from their screens.
Is Colgate's Cost Discipline Enough in a Softer Demand Cycle?
CL is leaning on productivity, AI and cost discipline to offset input inflation and protect margins amid uneven demand.
